GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes

July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association.

Egg Medical Launches EggNest Complete 2.0 Radiation Protection Device  

July 6, 2026—Egg Medical, a developer of enhanced radiation protection devices (ERPDs) for interventional procedures, announced the launch of its next-generation EggNest Complete 2.0 system.

Arizona Enacts Law on Radiation Protection Systems for Health Care Workers

July 6, 2026—A state law addressing the safety of staff in medical procedures involving ionizing radiation, lead aprons, radiation protection systems, and real-time dosimeters was enacted by Arizona Governor Kathy Hobbs on June 19.

IDE for TRIUMPH Pivotal Trial of Laplace’s TTVR System

July 2, 2026—Laplace Interventional, Inc. announced that the FDA has approved an investigational device exemption (IDE) for the TRIUMPH pivotal trial evaluating the company’s transcatheter tricuspid valve replacement (TTVR) system.

GE’s Allia Upgrade Pathways Introduced for Existing Interventional Suites

June 30, 2026—GE HealthCare announced the introduction of Allia platform upgrade pathways that are designed to help customers modernize select legacy Innova and Discovery image guiding solutions (IGS) systems.

Artivion’s AMDS Hybrid Prosthesis Approved by FDA

June 30, 2026—Artivion, Inc. announced that the FDA has approved the company’s AMDS hybrid prosthesis, an aortic arch remodeling device for use in the treatment of acute DeBakey type I aortic dissections with either clinical or radiographic malperfusion.

Terumo’s OpusWave Dual Sensor Imaging System Introduced in the United States

June 30, 2026—Terumo Interventional Systems, a division of Terumo Corporation, announced the completion of the first United States procedure using its OpusWave dual sensor imaging system.

Abbott Presents Data on TriClip TEER System, Navitor TAVR System, and Amulet 360 LAA Occluder 

June 29, 2026—Abbott announced the presentation of the first United States real-world outcomes of the company’s TriClip transcatheter edge-to-edge repair (TEER) system for the treatment of tricuspid regurgitation (TR) and data on the company’s Navitor transcatheter aortic valve replacement (TAVR) system to treat aortic stenosis.